Evidence Hub

Cytochrome P450 3A4-mediated pharmacokinetic interaction study between Tadalafil and Canagliflozin using High Performance Thin Layer Chromatography

A. B. H. Ali, Fatma A. M. Abdel-Aal, Azza H. Rageh, A. Mohamed

Journal of Separation Science, 2022

15 citations

Abstract

Diabetes is a known risk factor for sexual dysfunction in men; diabetic men have an increased risk of erectile dysfunction compared to non-diabetic men. Canagliflozin is one of the common antidiabetic drugs that readily used in treatment of type-2 diabetes. Concomitantly phosphodiesterase 5 inhibitors, such as tadalafil, can be given to the patient to alleviate erectile dysfunction. Canagliflozin is reported to be one of cytochrome P450 3A4 enzyme inhibitors, that might seriously influence blood concentration levels of tadalafil but there is no study till now discussed this interaction. Therefore, fast, simple and sensitive high performance thin-layer chromatographic method was developed, validated and applied for the simultaneous determination of tadalafil and canagliflozin in spiked and real human plasma. Limit of detection for tadalafil was 0.14 ng band-1 and for canagliflozin was 0.16 ng band-1 . Limit of quantitation value for tadalafil was 0.43 ng band-1 and for canagliflozin was 0.47 ng band-1 . Tadalafil and canagliflozin were determined simultaneously in real human plasma using the described procedure and the method was applied for in vivo pharmacokinetic drug interaction study between the studied drugs, which proved significant interaction between them, when administered simultaneously. This article is protected by copyright. All rights reserved.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free